General Information of Drug Off-Target (DOT) (ID: OT4M0JTZ)

DOT Name Hyaluronan mediated motility receptor (HMMR)
Synonyms Intracellular hyaluronic acid-binding protein; Receptor for hyaluronan-mediated motility; CD antigen CD168
Gene Name HMMR
Related Disease
Endometrial cancer ( )
Endometrial carcinoma ( )
Acute lymphocytic leukaemia ( )
Acute myelogenous leukaemia ( )
Adult glioblastoma ( )
Advanced cancer ( )
Bladder cancer ( )
Carcinoma ( )
Cervical cancer ( )
Cervical carcinoma ( )
Clear cell renal carcinoma ( )
Colon cancer ( )
Colon carcinoma ( )
Colorectal carcinoma ( )
Colorectal neoplasm ( )
Epithelial ovarian cancer ( )
Glioma ( )
Hepatitis B virus infection ( )
Hepatocellular carcinoma ( )
leukaemia ( )
Lung adenocarcinoma ( )
Matthew-Wood syndrome ( )
Metastatic malignant neoplasm ( )
Neoplasm ( )
Ovarian cancer ( )
Ovarian neoplasm ( )
Pancreatic cancer ( )
Plasma cell myeloma ( )
Polycystic ovarian syndrome ( )
Prostate cancer ( )
Prostate carcinoma ( )
Prostate neoplasm ( )
Renal cell carcinoma ( )
Small lymphocytic lymphoma ( )
Squamous cell carcinoma ( )
Urinary bladder cancer ( )
Urinary bladder neoplasm ( )
Breast neoplasm ( )
Osteoarthritis ( )
Rheumatoid arthritis ( )
Crohn disease ( )
Gastric cancer ( )
Glioblastoma multiforme ( )
Leukemia ( )
Lung neoplasm ( )
Lymphoma ( )
Non-small-cell lung cancer ( )
Stomach cancer ( )
UniProt ID
HMMR_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF15908 ; PF15905
Sequence
MSFPKAPLKRFNDPSGCAPSPGAYDVKTLEVLKGPVSFQKSQRFKQQKESKQNLNVDKDT
TLPASARKVKSSESKESQKNDKDLKILEKEIRVLLQERGAQDRRIQDLETELEKMEARLN
AALREKTSLSANNATLEKQLIELTRTNELLKSKFSENGNQKNLRILSLELMKLRNKRETK
MRGMMAKQEGMEMKLQVTQRSLEESQGKIAQLEGKLVSIEKEKIDEKSETEKLLEYIEEI
SCASDQVEKYKLDIAQLEENLKEKNDEILSLKQSLEENIVILSKQVEDLNVKCQLLEKEK
EDHVNRNREHNENLNAEMQNLKQKFILEQQEREKLQQKELQIDSLLQQEKELSSSLHQKL
CSFQEEMVKEKNLFEEELKQTLDELDKLQQKEEQAERLVKQLEEEAKSRAEELKLLEEKL
KGKEAELEKSSAAHTQATLLLQEKYDSMVQSLEDVTAQFESYKALTASEIEDLKLENSSL
QEKAAKAGKNAEDVQHQILATESSNQEYVRMLLDLQTKSALKETEIKEITVSFLQKITDL
QNQLKQQEEDFRKQLEDEEGRKAEKENTTAELTEEINKWRLLYEELYNKTKPFQLQLDAF
EVEKQALLNEHGAAQEQLNKIRDSYAKLLGHQNLKQKIKHVVKLKDENSQLKSEVSKLRC
QLAKKKQSETKLQEELNKVLGIKHFDPSKAFHHESKENFALKTPLKEGNTNCYRAPMECQ
ESWK
Function
Receptor for hyaluronic acid (HA). Involved in cell motility. When hyaluronan binds to HMMR, the phosphorylation of a number of proteins, including PTK2/FAK1 occurs. May also be involved in cellular transformation and metastasis formation, and in regulating extracellular-regulated kinase (ERK) activity. May act as a regulator of adipogenisis.
Tissue Specificity Expressed in testis . Expressed in the breast .
KEGG Pathway
ECM-receptor interaction (hsa04512 )
Reactome Pathway
AURKA Activation by TPX2 (R-HSA-8854518 )
Hyaluronan uptake and degradation (R-HSA-2160916 )

Molecular Interaction Atlas (MIA) of This DOT

48 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Endometrial cancer DISW0LMR Definitive Altered Expression [1]
Endometrial carcinoma DISXR5CY Definitive Altered Expression [1]
Acute lymphocytic leukaemia DISPX75S Strong Altered Expression [2]
Acute myelogenous leukaemia DISCSPTN Strong Biomarker [3]
Adult glioblastoma DISVP4LU Strong Biomarker [4]
Advanced cancer DISAT1Z9 Strong Altered Expression [5]
Bladder cancer DISUHNM0 Strong Biomarker [6]
Carcinoma DISH9F1N Strong Altered Expression [7]
Cervical cancer DISFSHPF Strong Altered Expression [8]
Cervical carcinoma DIST4S00 Strong Altered Expression [8]
Clear cell renal carcinoma DISBXRFJ Strong Altered Expression [9]
Colon cancer DISVC52G Strong Altered Expression [10]
Colon carcinoma DISJYKUO Strong Altered Expression [10]
Colorectal carcinoma DIS5PYL0 Strong Biomarker [11]
Colorectal neoplasm DISR1UCN Strong Altered Expression [12]
Epithelial ovarian cancer DIS56MH2 Strong Biomarker [13]
Glioma DIS5RPEH Strong Biomarker [14]
Hepatitis B virus infection DISLQ2XY Strong Biomarker [5]
Hepatocellular carcinoma DIS0J828 Strong Altered Expression [5]
leukaemia DISS7D1V Strong Biomarker [2]
Lung adenocarcinoma DISD51WR Strong Biomarker [15]
Matthew-Wood syndrome DISA7HR7 Strong Biomarker [16]
Metastatic malignant neoplasm DIS86UK6 Strong Biomarker [17]
Neoplasm DISZKGEW Strong Biomarker [18]
Ovarian cancer DISZJHAP Strong Biomarker [13]
Ovarian neoplasm DISEAFTY Strong Biomarker [13]
Pancreatic cancer DISJC981 Strong Biomarker [19]
Plasma cell myeloma DIS0DFZ0 Strong Altered Expression [20]
Polycystic ovarian syndrome DISZ2BNG Strong Biomarker [21]
Prostate cancer DISF190Y Strong Altered Expression [22]
Prostate carcinoma DISMJPLE Strong Altered Expression [22]
Prostate neoplasm DISHDKGQ Strong Altered Expression [23]
Renal cell carcinoma DISQZ2X8 Strong Altered Expression [24]
Small lymphocytic lymphoma DIS30POX Strong Biomarker [25]
Squamous cell carcinoma DISQVIFL Strong Altered Expression [26]
Urinary bladder cancer DISDV4T7 Strong Biomarker [6]
Urinary bladder neoplasm DIS7HACE Strong Biomarker [6]
Breast neoplasm DISNGJLM moderate Biomarker [27]
Osteoarthritis DIS05URM moderate Altered Expression [28]
Rheumatoid arthritis DISTSB4J moderate Altered Expression [28]
Crohn disease DIS2C5Q8 Limited Biomarker [29]
Gastric cancer DISXGOUK Limited Biomarker [30]
Glioblastoma multiforme DISK8246 Limited Biomarker [31]
Leukemia DISNAKFL Limited Biomarker [2]
Lung neoplasm DISVARNB Limited Biomarker [32]
Lymphoma DISN6V4S Limited Biomarker [29]
Non-small-cell lung cancer DIS5Y6R9 Limited Biomarker [32]
Stomach cancer DISKIJSX Limited Biomarker [30]
------------------------------------------------------------------------------------
⏷ Show the Full List of 48 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Drug Response of 1 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Vinblastine DM5TVS3 Approved Hyaluronan mediated motility receptor (HMMR) affects the response to substance of Vinblastine. [70]
------------------------------------------------------------------------------------
38 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate decreases the expression of Hyaluronan mediated motility receptor (HMMR). [33]
Ciclosporin DMAZJFX Approved Ciclosporin decreases the expression of Hyaluronan mediated motility receptor (HMMR). [34]
Tretinoin DM49DUI Approved Tretinoin decreases the expression of Hyaluronan mediated motility receptor (HMMR). [35]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Hyaluronan mediated motility receptor (HMMR). [36]
Doxorubicin DMVP5YE Approved Doxorubicin decreases the expression of Hyaluronan mediated motility receptor (HMMR). [37]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate decreases the expression of Hyaluronan mediated motility receptor (HMMR). [38]
Cisplatin DMRHGI9 Approved Cisplatin decreases the expression of Hyaluronan mediated motility receptor (HMMR). [39]
Estradiol DMUNTE3 Approved Estradiol decreases the expression of Hyaluronan mediated motility receptor (HMMR). [40]
Quercetin DM3NC4M Approved Quercetin decreases the expression of Hyaluronan mediated motility receptor (HMMR). [41]
Hydrogen peroxide DM1NG5W Approved Hydrogen peroxide affects the expression of Hyaluronan mediated motility receptor (HMMR). [42]
Calcitriol DM8ZVJ7 Approved Calcitriol decreases the expression of Hyaluronan mediated motility receptor (HMMR). [43]
Vorinostat DMWMPD4 Approved Vorinostat increases the expression of Hyaluronan mediated motility receptor (HMMR). [44]
Testosterone DM7HUNW Approved Testosterone decreases the expression of Hyaluronan mediated motility receptor (HMMR). [43]
Methotrexate DM2TEOL Approved Methotrexate decreases the expression of Hyaluronan mediated motility receptor (HMMR). [45]
Zoledronate DMIXC7G Approved Zoledronate decreases the expression of Hyaluronan mediated motility receptor (HMMR). [46]
Progesterone DMUY35B Approved Progesterone decreases the expression of Hyaluronan mediated motility receptor (HMMR). [47]
Niclosamide DMJAGXQ Approved Niclosamide decreases the expression of Hyaluronan mediated motility receptor (HMMR). [48]
Azathioprine DMMZSXQ Approved Azathioprine decreases the expression of Hyaluronan mediated motility receptor (HMMR). [49]
Aspirin DM672AH Approved Aspirin increases the expression of Hyaluronan mediated motility receptor (HMMR). [50]
Irinotecan DMP6SC2 Approved Irinotecan decreases the expression of Hyaluronan mediated motility receptor (HMMR). [51]
Paclitaxel DMLB81S Approved Paclitaxel decreases the expression of Hyaluronan mediated motility receptor (HMMR). [52]
Dasatinib DMJV2EK Approved Dasatinib decreases the expression of Hyaluronan mediated motility receptor (HMMR). [53]
Sulindac DM2QHZU Approved Sulindac decreases the expression of Hyaluronan mediated motility receptor (HMMR). [50]
Lucanthone DMZLBUO Approved Lucanthone decreases the expression of Hyaluronan mediated motility receptor (HMMR). [54]
Palbociclib DMD7L94 Approved Palbociclib decreases the expression of Hyaluronan mediated motility receptor (HMMR). [55]
Testosterone Undecanoate DMZO10Y Approved Testosterone Undecanoate increases the expression of Hyaluronan mediated motility receptor (HMMR). [56]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the expression of Hyaluronan mediated motility receptor (HMMR). [57]
(+)-JQ1 DM1CZSJ Phase 1 (+)-JQ1 decreases the expression of Hyaluronan mediated motility receptor (HMMR). [58]
Leflunomide DMR8ONJ Phase 1 Trial Leflunomide decreases the expression of Hyaluronan mediated motility receptor (HMMR). [59]
PMID28460551-Compound-2 DM4DOUB Patented PMID28460551-Compound-2 decreases the expression of Hyaluronan mediated motility receptor (HMMR). [60]
Bisphenol A DM2ZLD7 Investigative Bisphenol A decreases the expression of Hyaluronan mediated motility receptor (HMMR). [61]
Trichostatin A DM9C8NX Investigative Trichostatin A affects the expression of Hyaluronan mediated motility receptor (HMMR). [62]
Formaldehyde DM7Q6M0 Investigative Formaldehyde decreases the expression of Hyaluronan mediated motility receptor (HMMR). [63]
Coumestrol DM40TBU Investigative Coumestrol increases the expression of Hyaluronan mediated motility receptor (HMMR). [64]
Deguelin DMXT7WG Investigative Deguelin increases the expression of Hyaluronan mediated motility receptor (HMMR). [66]
Paraquat DMR8O3X Investigative Paraquat decreases the expression of Hyaluronan mediated motility receptor (HMMR). [67]
KOJIC ACID DMP84CS Investigative KOJIC ACID decreases the expression of Hyaluronan mediated motility receptor (HMMR). [68]
Dibutyl phthalate DMEDGKO Investigative Dibutyl phthalate decreases the expression of Hyaluronan mediated motility receptor (HMMR). [69]
------------------------------------------------------------------------------------
⏷ Show the Full List of 38 Drug(s)
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Sulforaphane DMQY3L0 Investigative Sulforaphane decreases the methylation of Hyaluronan mediated motility receptor (HMMR). [65]
------------------------------------------------------------------------------------

References

1 Expression of the Receptor for Hyaluronic Acid-Mediated Motility (RHAMM) in Endometrial Cancer is Associated With Adverse Histologic Parameters and Tumor Progression.Appl Immunohistochem Mol Morphol. 2020 Jul;28(6):453-459. doi: 10.1097/PAI.0000000000000763.
2 TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.Blood. 2012 Apr 12;119(15):3440-9. doi: 10.1182/blood-2011-06-357939. Epub 2012 Feb 27.
3 The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.Oncotarget. 2016 Nov 8;7(45):73960-73970. doi: 10.18632/oncotarget.12170.
4 COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.Oncotarget. 2017 Sep 15;8(50):87353-87363. doi: 10.18632/oncotarget.20928. eCollection 2017 Oct 20.
5 Hepatitis B Virus X Protein Induces RHAMM-Dependent Motility in Hepatocellular Carcinoma Cells via PI3K-Akt-Oct-1 Signaling.Mol Cancer Res. 2020 Mar;18(3):375-389. doi: 10.1158/1541-7786.MCR-19-0463. Epub 2019 Dec 2.
6 Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis.Cancer. 2011 Mar 15;117(6):1197-209. doi: 10.1002/cncr.25565. Epub 2010 Oct 19.
7 Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder.Oncol Rep. 2003 Jan-Feb;10(1):51-5.
8 A case of cervical cancer expressed three mRNA variant of Hyaluronan-mediated motility receptor.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2256-64. eCollection 2014.
9 Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.Exp Hematol. 2002 Sep;30(9):1029-35. doi: 10.1016/s0301-472x(02)00874-3.
10 Receptor for hyaluronan-mediated motility and CD44 expressions in colon cancer assessed by quantitative analysis using real-time reverse transcriptase-polymerase chain reaction.Jpn J Cancer Res. 1999 Sep;90(9):987-92. doi: 10.1111/j.1349-7006.1999.tb00846.x.
11 The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer.Oncotarget. 2017 Aug 3;8(41):70617-70629. doi: 10.18632/oncotarget.19904. eCollection 2017 Sep 19.
12 RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis.Clin Cancer Res. 2008 Jun 15;14(12):3798-806. doi: 10.1158/1078-0432.CCR-07-5103.
13 Increased RHAMM expression relates to ovarian cancer progression.J Ovarian Res. 2017 Sep 27;10(1):66. doi: 10.1186/s13048-017-0360-1.
14 Glioma infiltration and extracellular matrix: key players and modulators.Glia. 2018 Aug;66(8):1542-1565. doi: 10.1002/glia.23309. Epub 2018 Feb 21.
15 Identification of a novel glycolysis-related gene signature that can predict the survival of patients with lung adenocarcinoma.Cell Cycle. 2019 Mar;18(5):568-579. doi: 10.1080/15384101.2019.1578146. Epub 2019 Feb 17.
16 Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.Clin Cancer Res. 2018 Sep 15;24(18):4444-4454. doi: 10.1158/1078-0432.CCR-17-3401. Epub 2018 Apr 16.
17 Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases.Cancer Res. 2017 Apr 15;77(8):1905-1917. doi: 10.1158/0008-5472.CAN-16-1978. Epub 2017 Feb 14.
18 Galectin-3 Interacts with C/EBP and Upregulates Hyaluronan-Mediated Motility Receptor Expression in Gastric Cancer.Mol Cancer Res. 2020 Mar;18(3):403-413. doi: 10.1158/1541-7786.MCR-19-0811. Epub 2019 Dec 10.
19 Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells.Clin Cancer Res. 1996 Sep;2(9):1607-18.
20 Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells.Leuk Lymphoma. 2008 Mar;49(3):559-69. doi: 10.1080/10428190701824544.
21 Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.J Clin Endocrinol Metab. 2011 Jun;96(6):1737-46. doi: 10.1210/jc.2010-2600. Epub 2011 Mar 16.
22 RB Loss Promotes Prostate Cancer Metastasis.Cancer Res. 2017 Feb 15;77(4):982-995. doi: 10.1158/0008-5472.CAN-16-1589. Epub 2016 Dec 6.
23 Androgen receptor regulates CD168 expression and signaling in prostate cancer.Carcinogenesis. 2008 Feb;29(2):282-90. doi: 10.1093/carcin/bgm259. Epub 2008 Jan 3.
24 Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis.Cancer. 2012 May 1;118(9):2394-402. doi: 10.1002/cncr.26520. Epub 2011 Sep 1.
25 Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.Leukemia. 2010 Mar;24(3):563-72. doi: 10.1038/leu.2009.281. Epub 2010 Jan 14.
26 Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas.Int J Oncol. 2009 Jun;34(6):1565-71. doi: 10.3892/ijo_00000286.
27 Cell Cycle-Dependent Tumor Engraftment and Migration Are Enabled by Aurora-A.Mol Cancer Res. 2018 Jan;16(1):16-31. doi: 10.1158/1541-7786.MCR-17-0417. Epub 2017 Oct 9.
28 RHAMM induces progression of rheumatoid arthritis by enhancing the functions of fibroblast-like synoviocytes.BMC Musculoskelet Disord. 2018 Dec 26;19(1):455. doi: 10.1186/s12891-018-2370-6.
29 Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants.Blood. 1999 Mar 1;93(5):1684-96.
30 Hyaluronan-mediated motility receptor confers resistance to chemotherapy via TGF/Smad2-induced epithelial-mesenchymal transition in gastric cancer.FASEB J. 2019 May;33(5):6365-6377. doi: 10.1096/fj.201802186R. Epub 2019 Feb 25.
31 Targeting Long Noncoding RNA HMMR-AS1 Suppresses and Radiosensitizes Glioblastoma.Neoplasia. 2018 May;20(5):456-466. doi: 10.1016/j.neo.2018.02.010. Epub 2018 Mar 22.
32 Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells.Mol Carcinog. 2019 Mar;58(3):321-333. doi: 10.1002/mc.22930. Epub 2018 Nov 12.
33 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
34 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
35 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
36 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
37 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
38 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
39 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
40 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
41 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
42 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
43 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
44 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
45 Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
46 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
47 Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
48 Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
49 A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
50 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
51 In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
52 Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
53 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
54 Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25;286(8):6602-13.
55 Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
56 Levonorgestrel enhances spermatogenesis suppression by testosterone with greater alteration in testicular gene expression in men. Biol Reprod. 2009 Mar;80(3):484-92.
57 Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
58 The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene. 2016 Feb 18;35(7):833-45.
59 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
60 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
61 Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
62 A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
63 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
64 Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
65 Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020 Feb;136:111047. doi: 10.1016/j.fct.2019.111047. Epub 2019 Dec 12.
66 Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615. doi: 10.1007/s00204-020-02970-5. Epub 2021 Jan 29.
67 An in vitro strategy using multiple human induced pluripotent stem cell-derived models to assess the toxicity of chemicals: A case study on paraquat. Toxicol In Vitro. 2022 Jun;81:105333. doi: 10.1016/j.tiv.2022.105333. Epub 2022 Feb 16.
68 Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006 Apr;29(4):655-69.
69 In Vitro Exposure of Human Luteinized Mural Granulosa Cells to Dibutyl Phthalate Affects Global Gene Expression. Toxicol Sci. 2017 Nov 1;160(1):180-188. doi: 10.1093/toxsci/kfx170.
70 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.